Company intelligence / Profile preview
NovaOnco Therapeutics
Los Angeles, California, United Statesnovonco.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Novonco’s lead program, COH29, is a novel small molecule inhibitor of ribonucleotide reductase showing potent anti-tumor activity in preclinical models against BRCA1-deficient ovarian cancer and other hard-to-treat cancers. Preclinical data suggest it can overcome resistance to existing RNR inhibitors. First-in-human trials were planned at City of Hope. Two additional therapeutic platforms are under development via licensing from City of Hope and UC Irvine.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
City of Hope Beckman Research InstituteUniversity of California Irvine
Beyond the preview
Go deeper on NovaOnco Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovaOnco Therapeutics.